Clinical trials: sargramostim
Acute Myelogenous Leukemia, Ovarian Cancer
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer
- Trial name
- NCT03761914
- Testing
- galinpepimut-S, pembrolizumab, Montanide
- Where
- 12 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sellas Life Sciences Group
Drug Kinetics, Drug Effects on Physiology
Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Sargramostim Administered Subcutaneously, Intravenously, or by Inhalation
This single center, single ascending dose (SAD) and repeat dose study in healthy adults comprises 2 parts. Part 1 will consist of 6 SAD cohorts, in which different dose levels of sargramostim will be given by intravenous (IV)…
- Trial name
- NCT05366283
- Testing
- sargramostim
- Where
- Canada
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Partner Therapeutics, Inc.
HIV Infections
A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers
To evaluate the safety and immunogenicity of live recombinant canarypox ALVAC-HIV vCP205 in combination with recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) at 80 microg and 250 microg.
- Trial name
- NCT00001090
- Testing
- APL 400-047, ALVAC-HIV MN120TMG (vCP205), Sargramostim
- Where
- 4 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Prostate Cancer
GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere
This trial is designed to investigate the efficacy and safety of GM-CSF used as a maintenance program in patients with androgen-independent prostate cancer (AIPC) who have achieved a maximal response on a taxotere or other…
- Trial name
- NCT00274287
- Testing
- GM CSF
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Oncology Specialists, S.C.
Kidney Diseases, Kidney Transplant
Sargramostim for Myeloid Dendritic Cell Deficiency
The study will determine whether administration of sargramostim will improve myeloid dendritic cell deficiency in various study groups, including healthy subjects and patients with chronic kidney disease, including those with…
- Trial name
- NCT03063242
- Testing
- Sargramostim, Blood samples
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- University of Florida
Myeloma
Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant
The goal of this clinical research study is to learn if vaccinating a donor with your purified myeloma protein and then injecting it back into you will help your immune system control the multiple myeloma.
- Trial name
- NCT01174082
- Testing
- KLH Vaccine, KLH-id Vaccine, GM-CSF
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Pulmonary Alveolar Proteinosis, Autoimmune
SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study
Objective: Evaluate Pharmacokinetics and determine the safety of GM-CSF single dose inhalation. Study Design: Pharmacokinetic open study
- Trial name
- NCT02840708
- Testing
- Sargramostim
- Where
- Japan
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Niigata University Medical & Dental Hospital
Dendritic Cell Deficiency
Sargramostim for Myeloid Dendritic Cell Deficiency
Previous studies have demonstrated a deficiency of blood dendritic cells in patients with kidney disease that is associated with the development of viral infections after kidney transplantation.
- Trial name
- NCT01871467
- Testing
- Sargramostim
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
AML, ALL
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
Allogeneic stem cell transplantation may provide long-term remissions for some patients with hematological malignancies. However, allogeneic transplantation is associated with a significant risk of potentially life threatening…
- Conditions
- AML, ALL, CLL, Myelodysplastic Syndrome
- Trial name
- NCT00533923
- Testing
- Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Periodontitis
A Safety/Tolerability and Pharmakokinetic Study of Sargramostim Administrated in the Gingiva
This exploratory study is the first study in a clinical program where the overall objective is to develop a novel pharmaceutical therapy comprising local administration of GM-CSF for the treatment of periodontitis.
- Trial name
- NCT00689143
- Testing
- sargramostim
- Where
- Sweden
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Innoventus Project AB